Digitising the pharma supply chain
The Covid-19 pandemic has highlighted the need for security and traceability at every step of the drug supply chain.
Supply Chain
The dark consequences of drug supply shortages
Drug shortages caused by supply chain issues or political decisions can open the door to...
Global warning: pharma’s role in the climate crisis
With COP26 imminent, what lessons can the pharma sector learn about its environmental impact and...
Valneva could outsource Covid-19 vaccine manufacturing in response to demand
Valneva maps authorisation and manufacturing plans on the heels of positive Phase III Covid-19 vaccine...
Covid-19: vaccine pricing varies wildly by country and company
As the vaccine inequity debate rages on, even nations with access to Covid-19 jabs are...
Pharma’s reliance on horseshoe crabs is threatening the species
Conservationists say using the prehistoric creatures’ blood for bacterial endotoxin testing is no longer justifiable.
ICON Q&A: talking affordability in cell and gene therapies
ICON’s Tamie Joeckel discusses the challenges of making cell and gene therapies affordable for payers and patients alike.
Moderna to build $500m vaccine manufacturing facility in Africa
The company plans to build a factory capable of producing up to 500 million vaccine doses in the continent each year.
Generic drug safety: US regulators struggle to keep up with a global market
While foreign manufacturing inspections have increased, the challenges of properly regulating generics from non-US drugmakers remain.
Biologics packaging: unwrapping a complex challenge
The structural complexity of modern biologics presents packaging manufacturers with new challenges.
Why has the WHO asked governments to delay Covid-19 booster jabs?
While booster shots will likely be needed long-term, the WHO has argued that first jabs for poorer nations should be prioritised.
